Trials / Unknown
UnknownNCT05515185
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
An Open, Single-arm Clinical Study of Autologous T Cells (CAR-T) Targeting B7-H3 Chimeric Antigen Receptor Gene in the Treatment of Patients With Advanced Gastrointestinal Tumors
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First People's Hospital of Lianyungang · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.
Detailed description
This is a single-center, single-arm, open-label study. This study is planned to enroll about 30 subjects with advanced solid tumors. Autologous CAR-T cells were then infused intravenously into subjects, in a dose-escalating 3+3 design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KT095 CAR-T injection | Clearance of lymphocytes |
Timeline
- Start date
- 2022-09-09
- Primary completion
- 2024-09-08
- Completion
- 2024-09-08
- First posted
- 2022-08-25
- Last updated
- 2022-08-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05515185. Inclusion in this directory is not an endorsement.